L
ung transplantation is now a widely accepted option for treating cystic fibrosis (CF) patients with end-stage pulmonary disease. 1, 2 Reports of lung transplantation outcomes have come from the transplant centers. To our knowledge, there has been only one report that is based on the referral and transplant outcome experience from a CF clinical center. 3 In addition, the timing of transplantation (and, therefore, the timing of referral for evaluation) is critical. If referral is unduly delayed, the patient risks dying before a donor becomes available. However, approximately 40% of CF patients transplanted in the United States still die within 2 years of the procedure. 4 Therefore, premature referral and transplantation may compromise overall survival. Kerem et al, 5 reporting on 145 patients, suggest that since FEV 1 Ͻ 30% of predicted implies a 50% chance of death within 2 years, patients with this degree of pulmonary impairment should be considered for lung transplantation. This observation was supported by Grasemann et al, 6 but, more recently, Milla and Warwick 7 indicated a better prognosis.
Assessment of the potential usefulness of FEV 1 Ͻ 30% predicted as a criterion for transplantation eligibility requires estimating how these patients might have done if they had not undergone transplantation. We report our center's experience with survival after FEV 1 falls below 30% predicted in patients without transplants and our survival data after lung transplantation. Our data suggest that, if all CF patients with FEV 1 consistently Ͻ 30% were listed for transplant, overall life expectancy may be adversely affected.
Materials and Methods
CF was diagnosed by a positive sweat test together with typical pulmonary or digestive disease, or a positive family history. From 1991 to 1997, our patients have been referred to one of three lung transplant centers for evaluation. Twenty of these patients have subsequently undergone bilateral lung transplantation. The decision to refer for evaluation for transplantation candidacy included the results of pulmonary function tests, especially the percent predicted FEV 1 , the rate of deterioration of pulmonary function test scores, and the patient's overall morbidity (frequency and duration of hospitalizations; severity of pulmonary symptoms).
The following data were collected on all patients who subsequently underwent transplantation: age; gender; genotype; pulmonary microbiology; FEV 1 1 year before, at, and 1 year after referral; waiting time until transplantation; serum bicarbonate; percent ideal body weight (%IBW); and presence of diabetes at referral; survival after transplantation; and cause of death. FEV 1 was measured by standard technique 8, 9 and expressed as percent of predicted value. 10 Survival data were also gathered on all Burkholderia species-negative patients whose FEV 1 fell to Ͻ 30% predicted, before 1991 (when we referred our first patient for transplantation evaluation), and remained at that level at least 1 year.
Results
Between 1991 and 1997, 45 patients (23 male) were referred for lung transplantation. Nine patients (7 male) were not accepted for various reasons. Six patients died while awaiting a donor (waiting time: 2 to 20 months). Ten are still waiting (from 14 to 27 months after acceptance). One additional patient, who underwent transplantation within a few weeks of the completion of data collection for this article, is not included.
Twenty patients (12 male; age range: 11 to 39 years) have received bilateral sequential single lung transplants (BSLT). Seventeen of these patients had at least one F508 allele (11 homozygous, 3 confirmed compound heterozygote, and 3 presumed compound heterozygote). Only five patients (25%) waited Ͼ 1 year for transplant. A summary of demographic, clinical, and survival data for the patients with transplants is given in Table 1 , and Figures 1 and 2 .
Eight patients (four of whom survived Ͼ 1 year) had sufficient data to evaluate change in FEV 1 from 1 year preevaluation to 1 year postevaluation. FEV 1 ranged from 11 to 30% of predicted at referral with a mean decrease of 4% over the year prior to referral (four of the eight decreased Ն 5%), and 3.6% over the year following referral.
Serum bicarbonate levels were available on all 20 patients at referral with a range of 24 to 40 mmol/L. Four were normal; the rest showed mild-to-moderate elevations (range, 28 to 40) ( Table 1) . Whether serum bicarbonate level was elevated at referral did not seem to be correlated with outcome, in that elevation levels were almost equally distributed between Ͼ 2 years and Յ 1 year survival.
Five of the 20 patients (cases 3, 4, 11, 14, and 15) had insulin-dependent diabetes mellitus (IDDM) at transplant, including two who survived Ͼ 2 years. None of our patients had preparatory sinus surgery or sinus irrigation procedures. %IBW did not seem to be correlated with survival, and there was no value that offered firm predictive value. Six of eight patients with %IBW values Ͼ 85% survived for Ͻ 1 year, including the two patients with the highest values (cases 17 and 20; %IBW ϭ 105% and 106%, each of whom survived Ͻ 1 month), whereas two of eight patients with levels Ͻ 85% (including the patient with the lowest value (case 1; %IBW ϭ 64%) survived Ͼ 2 years.
During the year prior to referral, all but two patients (cases 1 and 9) had Pseudomonas aeruginosa (PA) recovered from sputum cultures and 18 had yeast. Ten had Staphylococcus aureus (SA), only one of which (case 6) was methicillin resistant. Of note, five had either Burkholderia cepacia (BC) (cases 1, 9, 15, 16) or Burkholderia gladioli (BG) (case 19). Although 10 of the 20 patients repeatedly had Aspergillus fumigatus (AF) recovered from sputum, this usually did not influence overall outcome as six were long-term survivors (Ͼ 45 months for five patients; 19 months for one other), and another 3 did not have further problems with this organism. However, one patient (case 20), whose pretransplant cultures had revealed AF, did die 3 weeks following transplant when there was erosion by this organism into one of the great vessels.
Bronchiolitis obliterans contributed to death in the two patients (cases 1 and 8) who died after 2 years (24 and 30 months) (Fig 2) . Ten deaths occurred within the first 18 months; nine of these patients died within 10 months. severe bilateral pleural adhesions with postoperative hemorrhage, disseminated cytomegalovirus, fungal sepsis, AF erosion into an artery, and BC with sepsis, respectively. Three others died of BG (case 19) or BC (cases 14 and 16) and one (case 13) of bronchiolitis obliterans at 5, 2, 10, and 5 months after BSLT, respectively. The tenth patient (case 9) died of BC complications at 17 months.
Valid pulmonary function studies for at least 2 consecutive years were available on 978 CF patients. Of the 338 who ever had an FEV 1 Ͻ 30% predicted, 178 met the following criteria: (1) no history of BC infection; and (2) FEV 1 Ͻ 30% predicted for Ն 1 year. Survival data on these patients were analyzed further. Survival (without transplant) ranged from a few months to Ͼ 20 years. The 178 patients were divided into three groups: those who reached the FEV 1 criterion before 1980; between 1980 (when ceftazidime became available to us) and 1986; and from 1986 (when oral quinolones began to be used extensively here, starting with the introduction of norfloxacin) through 1990 ( Table 2 ). The latter period ended just prior to our referring our first patient (case 12) for transplant evaluation. Table 2 shows the numbers of patients and the percent surviving for periods Ͼ 3 years for each of these groups. Of the 21 patients whose FEV 1 dropped to and remained Ͻ 30% for 1 year during 1986 to 1990, 15 (71%) had a Ͼ 3-year survival, and the median survival time improved to 4.6 years, with 25% living at least 9.2 years. The longest survivors to date are still alive at 11 years (Table 2) . Male survival (mean [Ϯ SD], 5.7 Ϯ 4.7 years) was not statistically different than female survival (mean, 4.7 Ϯ 3.6 years) (p ϭ 0.369) for 1980 to 1990.
Ideal body weight (percent predicted) was not different for male and female patients at the point when FEV 1 fell Ͻ 30% predicted. Furthermore, there was no difference between the %IBW of "short survivors" (below the median) vs "long survivors" (above the median) for either male patients (short survivors, 81.7%; long survivors, 80.3%) or female patients (short survivors, 82.8%; long survivors, 80.8%).
Discussion
To our knowledge, this is the first US-based report of survival data for CF patients with and without transplants. Our number of patients with transplants and survival was very similar to that of the Birmingham (Great Britain) Center, which is the only other report from a CF Clinical Center, to our knowledge. 3 Their patients with transplants were Ն 18 years, while our patients with transplants included three patients who were Ͻ 18 years of age. All our surviving patients are Ն 12 months posttransplant; four of their patients were at Յ 7 months. Both centers' 1-and 2-year survival (Cleveland, 55% and 45%; Birmingham, 58% and 52%) are worse than reported elsewhere. This may be due in part to the relatively large incidence of BC/BG infection (five in our series; six in Birmingham), which amounted to almost 25% of the combined patients.
The International Society for Heart and Lung Transplantation 1995 data indicated 1-, 2-, and 3.5-year survival for all double-lung transplantation of 67%, 60%, and 47%. 11 The St. Louis International Lung Transplant Registry 1997 7-year survival data for 5,910 patients revealed 1-, 2-, and 5-year survivals of 71%, 63%, and 46%. 4 CHEST / 115 / 3 / MARCH, 1999
For CF patients, one center has reported a 1-and 2-year survival of 85%/67%. 12 Three centers reported 1-year CF survivals of 58%, 13 64%, 14 and 65%. 15 The combined 1996 St. Louis Registry Data for CF revealed 1-and 2-year actuarial survival of 72% and 64%. 4 Our poor survival in BC/BG-colonized patients with transplants is consistent with transplant center reports. 16, 17 Survival in our patients (Table 1) did not seem to be correlated with any of the following: genotype, sex, age, presence of multiply resistant pathogens (other than Burkholderia species), yeast, aspergillus, SA, or Stenotrophomonas maltophilia on cultures, serum bicarbonate, IDDM, FEV 1 percent predicted, or rate of FEV 1 decline. Unexpectedly, %IBW also did not seem correlated to posttransplant survival.
To assess the potential impact of lung transplantation on overall survival, we compared our non-BCcolonized patients with transplants with all BCnegative patients without transplants whose FEV 1 remained Ͻ 30% predicted for at least 1 year. %IBW was not predictive of survival in male or female patients without transplants.
Our criteria of FEV 1 Ͻ 30% predicted for at least 1 year and the absence of BC differs from Kerem et al 5 (who included only patients who had died and did not exclude BC) and from Milla and Warwick 7 (who did include surviving patients, but did not have the 1-year FEV 1 criterion or the BC exclusion). Thus, Kerem et al 5 would not have included surviving patients with FEV 1 Ͻ 30% predicted. Furthermore, our requirement that the FEV 1 stay Ͻ 30% predicted for 1 year excludes patients whose pulmonary function rapidly deteriorated and then recovered after resolution of an acute illness.
At our center, survival of these patients with very advanced pulmonary disease has continued to improve recently (1986 to 1990), quite possibly related to our extensive use of the oral quinolones. During that time, we observed survival percentages of 57% for Ն 4 years and 48% survival for Ͼ 5 years. The median survival and upper quartile survival both increased for each time period reaching almost 7 years for 1980 to 1985 and over 9 years for 1986 to 1990.
Based on the St. Louis Registry data 4 (64% 2-year survival), we would predict that the average CF patient from our center referred for transplantation evaluation when the FEV 1 fell Ͻ 30% predicted for at least 1 year, and who then receives a transplant 2 years later, would, at that point, have had approximately a 64% chance to survive an additional 2 years (4-year total). An identical patient from our center who was not referred for transplant actually had a 57% chance of surviving the same 4 years. The St.
Louis 5-year posttransplant survival data (46%) is no better than our survival for similar patients without transplants (48%). Of course, some patients with transplants would have a markedly increased quality of life and some would have the possibility of truly long survival. However, those who would die within 2 years anyway would probably have had considerable pretransplant stress (waiting for the donor, perhaps moving to a strange city, additional expense, etc) and would have undergone considerable postoperative pain, not to mention the expense of the procedure itself and follow-up treatment. Similar considerations apply to those patients who "die waiting."
There is no doubt that the fall of the FEV 1 Ͻ 30% predicted is a measurable marker for more severe pulmonary involvement 18 and, in two centers' reports, 5, 6 predicts 50% mortality within 2 years. In such centers, this finding should certainly prompt consideration for transplant. However, our experience, like that of Milla and Warwick, 7 differs, and suggests that, at least at some other centers, this degree of pulmonary function abnormality is not as ominous and should not necessarily qualify the patient for consideration for transplantation. Additional medical considerations, recommended by others, 12, 19, 20 include gender, the rate of FEV 1 decline, the frequency of IV antibiotic therapy, response to intensive treatment, oxygen requirement, weight loss, presence of resistant or multiply resistant organisms, quality of life, and perceived life expectancy. Evaluation of psychological factors, availability of supportive persons, and short-and long-term financial support are also thought to be important for successful outcome.
At our center, a fall of FEV 1 to Ͻ 30% predicted for at least 1 year is not as ominous as previously reported, 5, 6 but it may still be a reasonable point for initiation of discussion about lung transplantation. 21 However, since a substantial number of our patients have survived for long periods after that event, the decision to accept such a patient for transplantation candidacy should not be considered automatic or immutable. If the patient's condition improves or stabilizes while waiting for a donor, temporary removal from the "active" transplant list may be prudent. The length of survival of such a patient may be better without transplant, and "reactivation" can be done when disease progression is again evident.
